Mentions
Extended reach
Total likes
Video views
AI synopsis
The group of discussions express strong support for the research's conclusions, with phrases like 'promising findings' and 'significant reduction' pointing to high agreement and perceived importance. The interest is reflected in how users focus on the potential for these medications to reduce dementia risk, while engagement is shown through references to specific trials and statistical data, indicating a meaningful comprehension and consideration of the study's implications.
Most discussions support the findings that GLP-1 receptor agonists may reduce dementia risk, with multiple posts emphasizing the positive implications.
The posts demonstrate high curiosity and attention to the new research, highlighting its potential significance and implications for treatment.
Some discussions reference specific studies, clinical trials, and statistical results, indicating a moderate depth of engagement with the research details.
The discussions highlight the promising potential of these medications to influence dementia prevention strategies, suggesting high real-world impact.
In a review and meta-analysis of randomized clinical trials, glucose-lowering therapy with GLP1-RAs, but not SGLT2is, was associated with a statistically significant reduction in dementia or cognitive impairment @JAMANeuro https://t.co/2j0PPtlUhy #Alzheimersdisease #T2D
Glucose-lowering therapy with GLP1-RAs, but not SGLT2 inhibitors, was associated with a statistically significant reduction in dementia or cognitive impairment. https://t.co/Ls9ARdWHfn https://t.co/dDR8Agfq0Y
Glucose-lowering therapy with GLP1-RAs, but not SGLT2 inhibitors, was associated with a statistically significant reduction in dementia or cognitive impairment. https://t.co/T1VjxmV5ok https://t.co/DacCTHVRy3
Source: https://t.co/UB9KtkGcpb
Glucose-lowering therapy with GLP1-RAs, but not SGLT2 inhibitors, was associated with a statistically significant reduction in dementia or cognitive impairment. https://t.co/GMDK7D2YIJ https://t.co/6ipVJqrlKN
Glucose-lowering therapy with GLP1-RAs, but not SGLT2 inhibitors, was associated with a statistically significant reduction in dementia or cognitive impairment. https://t.co/BHmer5yjwx
This video explores the findings of a systematic review and meta-analysis on cardioprotective glucose-lowering agents and their association with dementia risk. Published in JAMA Neurology, the study highlights…
GLP-1 drugs like Ozempic might do more than just help you lose weight. A new study suggests they could also reduce dementia risk by 45%. This video summarizes the latest evidence on GLP-1s and their potential effects on…
+ bibliografía @PubMedOnline Cardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta-Analysis Allie Seminer et al. JAMA Neurol. 2025. pubmed.ncbi.nlm.nih.gov/40193122/ Full text links pmc.ncbi.nlm.nih.gov/articles/PMC11…
+ bibliografía @PubMedOnline Cardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta-Analysis Allie Seminer et al. JAMA Neurol. 2025. https://t.co/RDBUocuC3O Full text links https://t.co/A5BKYpIozp https://t.co/esiErGIofn
Cardioprotective Glucose-Lowering Agents and Dementia Risk https://t.co/b12EaGz169
RT @neurochecklists: Cardioprotective Glucose-Lowering Agents and Dementia RiskA Systematic Review and Meta-Analysis https://t.co/GLXyvuPgZ…
RT @neurochecklists: Cardioprotective Glucose-Lowering Agents and Dementia RiskA Systematic Review and Meta-Analysis https://t.co/GLXyvuPgZ…
Cardioprotective Glucose-Lowering Agents and Dementia RiskA Systematic Review and Meta-Analysis https://t.co/GLXyvuPgZX https://t.co/7fglb6rfGF
Read the Original Investigation “Cardioprotective Glucose-Lowering Agents and Dementia Risk.” https://t.co/BEikRTUAt1
ادامه.https://t.co/fUyV6RA71k
RT @JAMANeuro: Glucose-lowering therapy with GLP1-RAs, but not SGLT2 inhibitors, was associated with a statistically significant reduction…
RT @JAMANeuro: Glucose-lowering therapy with GLP1-RAs, but not SGLT2 inhibitors, was associated with a statistically significant reduction…
RT @JAMANeuro: Glucose-lowering therapy with GLP1-RAs, but not SGLT2 inhibitors, was associated with a statistically significant reduction…
RT @JAMANeuro: Glucose-lowering therapy with GLP1-RAs, but not SGLT2 inhibitors, was associated with a statistically significant reduction…
RT @JAMANeuro: Glucose-lowering therapy with GLP1-RAs, but not SGLT2 inhibitors, was associated with a statistically significant reduction…
RT @JAMANeuro: Glucose-lowering therapy with GLP1-RAs, but not SGLT2 inhibitors, was associated with a statistically significant reduction…
RT @JAMANeuro: Glucose-lowering therapy with GLP1-RAs, but not SGLT2 inhibitors, was associated with a statistically significant reduction…
RT @JAMANeuro: Glucose-lowering therapy with GLP1-RAs, but not SGLT2 inhibitors, was associated with a statistically significant reduction…
RT @JAMANeuro: Glucose-lowering therapy with GLP1-RAs, but not SGLT2 inhibitors, was associated with a statistically significant reduction…
RT @JAMANeuro: Glucose-lowering therapy with GLP1-RAs, but not SGLT2 inhibitors, was associated with a statistically significant reduction…
Glucose-lowering therapy with GLP1-RAs, but not SGLT2 inhibitors, was associated with a statistically significant reduction in dementia or cognitive impairment. https://t.co/T1VjxmV5ok https://t.co/DacCTHVRy3
【GLP-1RAが認知症リスク低下と関連（メタ解析）（JAMA Neuro）】 26RCTのメタ解析 N = 164,531名、64歳で、35%が女性 認知症発症との関連は、 GLP-1RAで 45%低下（OR 0.55） SGLT2iでは関連なし（OR 1.20） 特にGLP-1RAと脳血管性認知症リスク低下との関連が強い https://t.co/bsWzMkXbp1 https://t.co/D9eLy7R7l0
Cardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta-Analysis | Dementia and Cognitive Impairment | JAMA Neurology | JAMA Network https://t.co/IDUysTi682
Cardioprotective Glucose-Lowering Agents and Dementia Risk
People with diabetes often worry about memory loss or developing dementia. A new study shows that one group of diabetes medications-GLP-1 receptor agonists-may help lower the risk of dementia.https://t.co/ROFl3SRpOu
Cardioprotective Glucose-Lowering Agents and Dementia Risk https://t.co/HrUL48VWBg
In this meta-analysis of randomized clinical trials, glucose-lowering therapy with GLP1-RAs, but not SGLT2is, was associated with a statistically significant reduction in dementia or cognitive impairment https://t.co/jByQwTy5Xx
RT @3stars67664378:
RT @cremieuxrecueil: Source: https://t.co/UB9KtkGcpb
Source: https://t.co/UB9KtkGcpb
Here's the meta-analysis on dementia in JAMA: https://t.co/CYpMU05hZV
RT @daperezm: Prometedor hallazgo para esta clase de fármacos. Se ha publicado en JAMA Neurology.
RT @JAMANeuro: Glucose-lowering therapy with GLP1-RAs, but not SGLT2 inhibitors, was associated with a statistically significant reduction…
RT @JAMANeuro: Glucose-lowering therapy with GLP1-RAs, but not SGLT2 inhibitors, was associated with a statistically significant reduction…
Glucose-lowering therapy with GLP1-RAs, but not SGLT2 inhibitors, was associated with a statistically significant reduction in dementia or cognitive impairment. https://t.co/GMDK7D2YIJ https://t.co/6ipVJqrlKN
Cardioprotective Glucose-Lowering Agents and Dementia Risk A Systematic Review and Meta-Analysis https://t.co/AfJfDBPSip
【システマティックレビュー・メタアナリシス】心保護血糖降下薬（SGLT2阻害薬、GLP-1RA、メトホルミン、ピオグリタゾン）および認知症リスク（心保護血糖降下薬全体では認知機能障害や認知症オッズ減少と関連しなかった。GLP-1RAは認知症のオッズ低下と関連した。） #ペ読 https://t.co/gGwGeZp8ai
Prometedor hallazgo para esta clase de fármacos. Se ha publicado en JAMA Neurology.
Cardioprotective Glucose-Lowering Agents and Dementia Risk https://t.co/e9ExgRJmLZ
RT @JAMANeuro: Glucose-lowering therapy with GLP1-RAs, but not SGLT2 inhibitors, was associated with a statistically significant reduction…
RT @angelopezh: Agentes reductores de glucosa cardioprotectores y riesgo de demencia: una revisión sistemática y metanálisis | Demencia y d…
Cardioprotective Glucose-Lowering Agents and Dementia Risk https://t.co/2lHpPbnYZM
RT @JAMANeuro: Glucose-lowering therapy with GLP1-RAs, but not SGLT2 inhibitors, was associated with a statistically significant reduction…
RT @JAMANeuro: Glucose-lowering therapy with GLP1-RAs, but not SGLT2 inhibitors, was associated with a statistically significant reduction…
Glucose-lowering therapy with GLP1-RAs, but not SGLT2 inhibitors, was associated with a statistically significant reduction in dementia or cognitive impairment. https://t.co/Ls9ARdWHfn https://t.co/dDR8Agfq0Y
RT @angelopezh: Agentes reductores de glucosa cardioprotectores y riesgo de demencia: una revisión sistemática y metanálisis | Demencia y d…
@pash22 @adamcifu @FrijtersPaul @EpiEllie @VPrasadMDMPH @drjohnm You know, it is an ironic miracle, dementia is going to disappear with drugs unrelated to dementia (because dementia drugs do not work)... Also glucose lowering with GLP-1RAs was associated with a statistically significant reduction in all-cause dementia. https://t.co/AJLy5Yo1bQ
Dos nuevos estudios y un editorial en la revista científica JAMA Neurology que sugieren que este tipo de fármacos también podrían contribuir a reducir el riesgo de desarrollar demencia: https://t.co/xKK7Q8CEiA https://t.co/mzoK2Z44kN https://t.co/7m3JnC61tO
RT @angelopezh: Agentes reductores de glucosa cardioprotectores y riesgo de demencia: una revisión sistemática y metanálisis | Demencia y d…
Agentes reductores de glucosa cardioprotectores y riesgo de demencia: una revisión sistemática y metanálisis | Demencia y deterioro cognitivo | JAMA Neurología | JAMA Network https://t.co/3NetYLrGYz
En este metaanálisis de ensayos clínicos aleatorizados, se evaluó el efecto de tx hipoglucemiantes sobre el riesgo de demencia. Las GLP-1 mostraron una reducción significativa del riesgo, mientras que las SGLT2 y piogltazn no. JAMA Neurol. 2025. doi:10.1001/jamaneurol.2025.0360 https://t.co/rApCz9NfZV
RT @DanielJDrucker: In a review and meta-analysis of randomized clinical trials, glucose-lowering therapy with GLP1-RAs, but not SGLT2is, w…
RT @JAMANeuro: Glucose-lowering therapy with GLP1-RAs, but not SGLT2 inhibitors, was associated with a statistically significant reduction…
RT @JAMANeuro: Glucose-lowering therapy with GLP1-RAs, but not SGLT2 inhibitors, was associated with a statistically significant reduction…
RT @JAMANeuro: Glucose-lowering therapy with GLP1-RAs, but not SGLT2 inhibitors, was associated with a statistically significant reduction…
RT @JAMANeuro: Glucose-lowering therapy with GLP1-RAs, but not SGLT2 inhibitors, was associated with a statistically significant reduction…
Glucose-lowering therapy with GLP1-RAs, but not SGLT2 inhibitors, was associated with a statistically significant reduction in dementia or cognitive impairment. https://t.co/sgK76eGH1n
RT @DanielJDrucker: In a review and meta-analysis of randomized clinical trials, glucose-lowering therapy with GLP1-RAs, but not SGLT2is, w…
https://t.co/PYAezifuqV
RT @DanielJDrucker: In a review and meta-analysis of randomized clinical trials, glucose-lowering therapy with GLP1-RAs, but not SGLT2is, w…
RT @DanielJDrucker: In a review and meta-analysis of randomized clinical trials, glucose-lowering therapy with GLP1-RAs, but not SGLT2is, w…
RT @DanielJDrucker: In a review and meta-analysis of randomized clinical trials, glucose-lowering therapy with GLP1-RAs, but not SGLT2is, w…
(JAMA) Hipoglucemiantes cardioprotectores y el riesgo de demencia https://t.co/uK8wqHyF8f Rev Sist y MA https://t.co/kdQIiWTtym Editorial https://t.co/WsBqhd3hrX
RT @DanielJDrucker: In a review and meta-analysis of randomized clinical trials, glucose-lowering therapy with GLP1-RAs, but not SGLT2is, w…
RT @DanielJDrucker: In a review and meta-analysis of randomized clinical trials, glucose-lowering therapy with GLP1-RAs, but not SGLT2is, w…
Cardioprotective Glucose-Lowering Agents and Dementia Risk A Systematic Review and Meta-Analysis jamanetwork.com/journals/jam...
Cardioprotective Glucose-Lowering Agents and Dementia Risk A Systematic Review and Meta-Analysis https://t.co/4BYpOTQ91j
RT @DanielJDrucker: In a review and meta-analysis of randomized clinical trials, glucose-lowering therapy with GLP1-RAs, but not SGLT2is, w…
RT @DanielJDrucker: In a review and meta-analysis of randomized clinical trials, glucose-lowering therapy with GLP1-RAs, but not SGLT2is, w…
Cardioprotective Glucose-Lowering Agents & Dementia Risk: Systematic Review Meta-Analysis. 26 RCTs ;(N = 164531), 23 trials (n = 160191) on dementia or cognitive impairment, 12 trials on SGLT2is, 10 trials on GLP-1RAs, 1 trial on pioglitazone. https://t.co/p6bKMgo14Q
RT @DanielJDrucker: In a review and meta-analysis of randomized clinical trials, glucose-lowering therapy with GLP1-RAs, but not SGLT2is, w…
Cardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta-Analysis | Dementia and Cognitive Impairment | JAMA Neurology | JAMA Network https://t.co/Zz1FzNyie6
RT @DanielJDrucker: In a review and meta-analysis of randomized clinical trials, glucose-lowering therapy with GLP1-RAs, but not SGLT2is, w…
RT @DanielJDrucker: In a review and meta-analysis of randomized clinical trials, glucose-lowering therapy with GLP1-RAs, but not SGLT2is, w…
RT @DanielJDrucker: In a review and meta-analysis of randomized clinical trials, glucose-lowering therapy with GLP1-RAs, but not SGLT2is, w…
RT @DanielJDrucker: In a review and meta-analysis of randomized clinical trials, glucose-lowering therapy with GLP1-RAs, but not SGLT2is, w…
Cardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta-Analysis | Dementia and Cognitive Impairment | JAMA Neurology | JAMA Network https://t.co/fBMFQKQCP3
RT @MariAngelesMoro: Cardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta-Analysis | Dementia and Cogni…
RT @DanielJDrucker: In a review and meta-analysis of randomized clinical trials, glucose-lowering therapy with GLP1-RAs, but not SGLT2is, w…
RT @DanielJDrucker: In a review and meta-analysis of randomized clinical trials, glucose-lowering therapy with GLP1-RAs, but not SGLT2is, w…
RT @DanielJDrucker: In a review and meta-analysis of randomized clinical trials, glucose-lowering therapy with GLP1-RAs, but not SGLT2is, w…
Cardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta-Analysis | Dementia and Cognitive Impairment | JAMA Neurology | JAMA Network https://t.co/XdAfj9nXbf
Cardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta-Analysis | Dementia and Cognitive Impairment | JAMA Neurology | JAMA Network
Recent epidemiological studies report substantial dementia risk reductions (45%, 54%, 20%). Surprisingly large effects compared to amyloid-beta antibodies. Ozempic: https://t.co/5GTmEj8UXr Viagra: https://t.co/zsQsK19bDd Shingles vaccine: https://t.co/rbylJaQIRz
RT @DanielJDrucker: In a review and meta-analysis of randomized clinical trials, glucose-lowering therapy with GLP1-RAs, but not SGLT2is, w…
In this meta-analysis of randomized clinical trials, glucose-lowering therapy with GLP1-RAs, but not SGLT2is, was associated with a statistically significant reduction in dementia or cognitive impairment. https://t.co/4ZfstsqADK
Cardioprotective Glucose-Lowering Agents and Dementia Risk A Systematic Review and Meta-Analysis. https://t.co/4ZfstsqADK
@Medscape Oh of course, primary source here: https://t.co/WhfFaULSRt
RT @DanielJDrucker: In a review and meta-analysis of randomized clinical trials, glucose-lowering therapy with GLP1-RAs, but not SGLT2is, w…
RT @DanielJDrucker: In a review and meta-analysis of randomized clinical trials, glucose-lowering therapy with GLP1-RAs, but not SGLT2is, w…
RT @DanielJDrucker: In a review and meta-analysis of randomized clinical trials, glucose-lowering therapy with GLP1-RAs, but not SGLT2is, w…
RT @DanielJDrucker: In a review and meta-analysis of randomized clinical trials, glucose-lowering therapy with GLP1-RAs, but not SGLT2is, w…
RT @rkalyes1: ✍️
RT @JAMANeuro: Glucose-lowering therapy with GLP1-RAs, but not SGLT2 inhibitors, was associated with a statistically significant reduction…
RT @DanielJDrucker: In a review and meta-analysis of randomized clinical trials, glucose-lowering therapy with GLP1-RAs, but not SGLT2is, w…
RT @DrYukselUrun:
RT @DrYukselUrun:
✍️
RT @DanielJDrucker: In a review and meta-analysis of randomized clinical trials, glucose-lowering therapy with GLP1-RAs, but not SGLT2is, w…
RT @DanielJDrucker: In a review and meta-analysis of randomized clinical trials, glucose-lowering therapy with GLP1-RAs, but not SGLT2is, w…
RT @DanielJDrucker: In a review and meta-analysis of randomized clinical trials, glucose-lowering therapy with GLP1-RAs, but not SGLT2is, w…
https://t.co/dbV9fWwc2q
RT @DanielJDrucker: In a review and meta-analysis of randomized clinical trials, glucose-lowering therapy with GLP1-RAs, but not SGLT2is, w…
Glucose-lowering therapy with GLP1-RAs, but not SGLT2 inhibitors, was associated with a statistically significant reduction in dementia or cognitive impairment. https://t.co/BHmer5yjwx
RT @DanielJDrucker: In a review and meta-analysis of randomized clinical trials, glucose-lowering therapy with GLP1-RAs, but not SGLT2is, w…
RT @DanielJDrucker: In a review and meta-analysis of randomized clinical trials, glucose-lowering therapy with GLP1-RAs, but not SGLT2is, w…
RT @DanielJDrucker: In a review and meta-analysis of randomized clinical trials, glucose-lowering therapy with GLP1-RAs, but not SGLT2is, w…
In a review and meta-analysis of randomized clinical trials, glucose-lowering therapy with GLP1-RAs, but not SGLT2is, was associated with a statistically significant reduction in dementia or cognitive impairment @JAMANeuro https://t.co/2j0PPtlUhy #Alzheimersdisease #T2D